Eden Research (LON:EDEN) Trading Down 13.2% – Should You Sell?

Posted by ABMN Staff on Apr 1st, 2025

Eden Research plc (LON:EDEN – Get Free Report) shares fell 13.2% during trading on Tuesday . The company traded as low as GBX 2.26 ($0.03) and last traded at GBX 2.37 ($0.03). 1,775,147 shares changed hands during trading, an increase of 133% from the average session volume of 762,776 shares. The stock had previously closed at GBX 2.73 ($0.04).

Eden Research Price Performance

The company has a debt-to-equity ratio of 1.26, a current ratio of 3.80 and a quick ratio of 2.42. The company has a market cap of £12.27 million, a PE ratio of -8.06 and a beta of 0.92. The company has a 50-day moving average price of GBX 3.39 and a two-hundred day moving average price of GBX 3.72.

Insiders Place Their Bets

In other Eden Research news, insider Lykele van der Broek acquired 256,000 shares of the stock in a transaction on Thursday, February 6th. The stock was purchased at an average price of GBX 4 ($0.05) per share, for a total transaction of £10,240 ($13,229.97). Also, insider Alexander John Abrey acquired 167,947 shares of the company’s stock in a transaction on Tuesday, March 4th. The shares were acquired at an average price of GBX 3 ($0.04) per share, for a total transaction of £5,038.41 ($6,509.57). Insiders purchased a total of 964,487 shares of company stock worth $3,690,001 in the last 90 days. 14.02% of the stock is owned by company insiders.

Eden Research Company Profile

(Get Free Report)

Eden Research is the only UK-listed company focused on biopesticides for sustainable agriculture. It develops and supplies innovative biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries.

Eden’s products are formulated with terpene active ingredients, based on natural plant defence metabolites.